SCHEMBL7713374

SCHEMBL7713374

CC1Oc2ccc(C(Cc3ccccc3)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.50
CCKAR P32238 1/20 0.45
CCKBR P32239 1/20 0.45
ALDH1A1 P00352 6/20 0.44
IDO1 P14902 1/20 0.43
HPGD P15428 5/20 0.43
HTT P42858 5/20 0.43
NPSR1 Q6W5P4 5/20 0.43
LMNA P02545 4/20 0.43
PKM P14618 3/20 0.43
HSD17B10 Q99714 3/20 0.43
TSHR P16473 3/20 0.43
KMT2A Q03164 2/20 0.43
XBP1 P17861 2/20 0.43
MEN1 O00255 1/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATM Q13315 2/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7713294 0.92 PARP1 (0.42) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7713338 0.91 PARP1 (0.42) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7708144 0.91 PARP1 (0.42) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7713251 0.90 CTSS (0.45) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7711091 0.90 PARP1 (0.42) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7711137 0.90 CTSL (0.45) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7711371 0.90 PARP1 (0.41) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7704943 0.90 ALDH1A1 (0.43) PARP1CCKARCCKBRALDH1A1HPGD
SCHEMBL7708029 0.89 PARP1 (0.41) PARP1CCKARCCKBRALDH1A1IDO1
SCHEMBL7708220 0.89 PARP1 (0.41) PARP1CCKARCCKBRALDH1A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed